New data highlights the value of AlloSure to detect rejection in one of the most complex transplanted organs
LOS ANGELES, CA, UNITED STATES - Feb 21, 2019 -
https://globenewswire.com/news-release/2019/02/21/1739290/0/en/AlloSure-now-available-for-Lung-Transplant-Patients.html
February 21, 2019 08:00 ET
|
Source:
CareDx, Inc.
BRISBANE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that AlloSure is now available under a compassionate use program for lung transplant patients.
AlloSure Lung is the next addition to the CareDx portfolio of transplant surveillance services, alongside AlloSure Kidney and AlloSure Heart. Lung transplant patients have the lowest survival rate of any solid organ transplant, and there are few options for rejection monitoring. AlloSure Lung directly addresses this unmet need with a noninvasive blood test. CareDx will be making AlloSure Lung available for this high need patient population through a compassionate use program while the test is undergoing further studies. Caregivers and patients are encouraged to contact CareDx for more details.
There is an incredible unmet need for blood based surveillance in this patient population, said Peter Maag, Chief Executive Officer at CareDx. We have built a great body of evidence and together with recent publications, we believe it is best for patients to offer AlloSure now under compassionate use.
I am glad to see the donor derived cell free DNA technology become broadly available for clinical care of lung transplant patients, said Mark Nicolls, Professor in Pulmonary Medicine at Stanford University. Recent research at the National Heart, Lung, and Blood Institute provides the clinical evidence demonstrating the potential value a commercial test can bring to this underserved patient population.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit:
www.CareDx.com
.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the availability of AlloSure under a compassionate use program for lung transplant patients. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDxs filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by CareDx with the SEC on March 22, 2018 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDxs actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDxs forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.